Burning Rock Biotech Limited American Depositary Shares - BNR STOCK NEWS

Burning Rock Biotech Limited (NASDAQ: BNR, LSE: BNR) announced plans to release its unaudited financial results for Q1 2023 on May 30, 2023, before U.S. market opens. Management will hold a conference call at 8:00 a.m. ET on the same day. The company anticipates moderate revenue growth year-over-year, driven by a strong rebound in March, reversing previous declines in January-February. March 2023 total test volumes increased by approximately 29% year-over-year, attributed mainly to growth in the in-hospital channel. Investors can register for the call and access a live webcast on the company’s investor relations website.

Burning Rock Biotech Limited (NASDAQ: BNR), focused on next-generation sequencing technology for precision oncology, filed its Annual Report on Form 20-F for the fiscal year ending December 31, 2022, with the U.S. SEC on April 21, 2023. The report is accessible on both the SEC website and the company's own site.

Burning Rock's business segments include NGS-based therapy selection testing for late-stage cancer patients and cancer early detection, which has advanced to the clinical validation phase. The company's mission remains centered on enhancing cancer care through scientific innovation.

Burning Rock Biotech Limited (NASDAQ: BNR) reported its financial results for the fourth quarter and full year 2022. The company recorded revenues of RMB142.2 million (US$20.6 million) for Q4 2022, a 3.5% decrease compared to Q4 2021, mainly due to COVID-19 impacts. For full-year 2022, revenues rose 10.9% to RMB563.2 million (US$81.7 million). The net loss for Q4 2022 was RMB216.2 million (US$31.4 million), improved from RMB251.1 million in Q4 2021. The company achieved a significant milestone with its Early Detection OverCTM test receiving Breakthrough Device Designation from the FDA. 2023 revenue guidance suggests an expected growth of approximately 20% over 2022.

Burning Rock Biotech Limited (NASDAQ: BNR) has announced plans to release its unaudited financial results for the fourth quarter and full year 2022 prior to the U.S. market opening on March 28, 2023. Following the results, management will host a conference call at 8:00 a.m. ET (8:00 p.m. Hong Kong time) to discuss the financial outcomes. The company focuses on next generation sequencing (NGS) technology in precision oncology, which includes therapy selection testing for late-stage cancer patients and early cancer detection now in clinical validation. Investors can pre-register for the conference call through the provided link.

Burning Rock Biotech Limited (NASDAQ: BNR) announced an expected 10% growth in full-year revenue for 2022, up from a previous estimate of 5%. This revision reflects better-than-anticipated fourth-quarter performance, despite a projected single-digit revenue decline in Q4 compared to 2021. Revenues from its central-lab and in-hospital segments are expected to decline by double digits, attributed to Covid-related disruptions. However, revenue from the pharma service segment is expected to grow at a triple-digit rate. The company will release its detailed Q4 and full-year results in March 2023, with current revenue estimates being preliminary and subject to change.

Burning Rock (NASDAQ/LSE: BNR), based in Irvine, California, has announced that its OverC™ Multi-Cancer Detection Blood Test (MCDBT) has been granted Breakthrough Device Designation by the US FDA, marking it as the third globally to receive this recognition. This designation supports the rapid development and review of medical devices for serious conditions like cancer. The OverC™ MCDBT targets early detection of multiple cancers, showing a 69.1% sensitivity and 98.9% specificity in preliminary studies. The technology aims to enhance early diagnosis and treatment efficiency, potentially improving patient survival rates.